Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.27 Million SEK | 31.99% |
| 2022 | 6.26 Million SEK | 179.2% |
| 2021 | 2.24 Million SEK | 68.54% |
| 2020 | 1.33 Million SEK | -6.59% |
| 2019 | 1.42 Million SEK | -21.13% |
| 2018 | 1.8 Million SEK | 194.25% |
| 2017 | 614.44 Thousand SEK | -83.11% |
| 2016 | 3.63 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 349.99 Thousand SEK | -0.14% |
| 2010 | 350.48 Thousand SEK | 75.24% |
| 2009 | 199.99 Thousand SEK | 33.33% |
| 2008 | 149.99 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 5.62 Million SEK | 79.04% |
| 2024 Q1 | 3.14 Million SEK | -29.53% |
| 2024 Q3 | 5.4 Million SEK | -3.79% |
| 2023 Q1 | 587 Thousand SEK | -86.33% |
| 2023 Q4 | 4.45 Million SEK | 125.28% |
| 2023 Q2 | 1.25 Million SEK | 113.29% |
| 2023 FY | 8.27 Million SEK | 31.99% |
| 2023 Q3 | 1.97 Million SEK | 57.99% |
| 2022 Q4 | 4.29 Million SEK | 385.86% |
| 2022 Q1 | 708 Thousand SEK | -47.32% |
| 2022 Q2 | 381 Thousand SEK | -46.19% |
| 2022 FY | 6.26 Million SEK | 179.2% |
| 2022 Q3 | 884 Thousand SEK | 132.02% |
| 2021 Q1 | 893 Thousand SEK | 2389.74% |
| 2021 Q3 | 7000.00 SEK | 600.0% |
| 2021 Q4 | 1.34 Million SEK | 19100.0% |
| 2021 FY | 2.24 Million SEK | 68.54% |
| 2021 Q2 | 1000.00 SEK | -99.89% |
| 2020 Q4 | -39 Thousand SEK | -104.8% |
| 2020 Q2 | 309 Thousand SEK | 23.6% |
| 2020 FY | 1.33 Million SEK | -6.59% |
| 2020 Q1 | 250 Thousand SEK | 110.08% |
| 2020 Q3 | 812 Thousand SEK | 162.78% |
| 2019 Q4 | 119 Thousand SEK | -87.38% |
| 2019 FY | 1.42 Million SEK | -21.13% |
| 2019 Q3 | 943 Thousand SEK | 258.56% |
| 2019 Q1 | 101 Thousand SEK | -75.43% |
| 2019 Q2 | 263 Thousand SEK | 160.4% |
| 2018 FY | 1.8 Million SEK | 194.25% |
| 2018 Q1 | 416.48 Thousand SEK | 32.46% |
| 2018 Q4 | 411.07 Thousand SEK | 203.74% |
| 2018 Q3 | 135.33 Thousand SEK | -83.99% |
| 2018 Q2 | 845.1 Thousand SEK | 102.91% |
| 2017 FY | 614.44 Thousand SEK | -83.11% |
| 2017 Q4 | 314.43 Thousand SEK | 4.81% |
| 2017 Q3 | 300.01 Thousand SEK | -87.69% |
| 2017 Q2 | 2.43 Million SEK | 1.75% |
| 2017 Q1 | 2.39 Million SEK | -1.43% |
| 2016 FY | 3.63 Million SEK | 0.0% |
| 2016 Q2 | 5945.00 SEK | 1.05% |
| 2016 Q1 | 5883.00 SEK | 105.51% |
| 2016 Q3 | 1.19 Million SEK | 20013.39% |
| 2016 Q4 | 2.42 Million SEK | 103.21% |
| 2015 Q3 | 1667.00 SEK | -98.44% |
| 2015 Q4 | -106.7 Thousand SEK | -6500.72% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q2 | 106.7 Thousand SEK | 9210.65% |
| 2015 Q1 | 1146.00 SEK | -99.99% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | 15.06 Million SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 100.0% |
| 2013 Q4 | -12 Thousand SEK | -200.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q3 | 12 Thousand SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 100.0% |
| 2012 Q4 | -123.13 Thousand SEK | 0.0% |
| 2012 Q2 | 23.13 Thousand SEK | -76.86% |
| 2012 Q1 | 99.99 Thousand SEK | -42.86% |
| 2012 FY | - SEK | -100.0% |
| 2012 Q3 | - SEK | -100.0% |
| 2011 Q3 | - SEK | -100.0% |
| 2011 Q2 | 175 Thousand SEK | 0.0% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q4 | 174.99 Thousand SEK | 0.0% |
| 2011 FY | 349.99 Thousand SEK | -0.14% |
| 2010 Q2 | 175 Thousand SEK | 0.0% |
| 2010 FY | 350.48 Thousand SEK | 75.24% |
| 2010 Q3 | - SEK | -100.0% |
| 2010 Q1 | - SEK | -100.0% |
| 2010 Q4 | 175.48 Thousand SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2009 Q1 | - SEK | 0.0% |
| 2009 FY | 199.99 Thousand SEK | 33.33% |
| 2009 Q4 | 199.99 Thousand SEK | 0.0% |
| 2009 Q3 | - SEK | 0.0% |
| 2008 FY | 149.99 Thousand SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| 2008 Q3 | - SEK | -100.0% |
| 2008 Q2 | 99.99 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -32.559% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.397% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.397% |
| Arcoma AB | 163.01 Million SEK | 94.925% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 95.944% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.631% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 98.552% |
| CellaVision AB (publ) | 677.29 Million SEK | 98.779% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -747.399% |
| C-Rad AB (publ) | 424.61 Million SEK | 98.052% |
| Duearity AB (publ) | 1.65 Million SEK | -400.181% |
| Dignitana AB (publ) | 86.06 Million SEK | 90.387% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 19.68% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.974% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -16.879% |
| Integrum AB (publ) | 104.11 Million SEK | 92.054% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -867.943% |
| Mentice AB (publ) | 273.61 Million SEK | 96.976% |
| OssDsign AB (publ) | 112.15 Million SEK | 92.624% |
| Paxman AB (publ) | 210.11 Million SEK | 96.063% |
| Promimic AB (publ) | 37.07 Million SEK | 77.683% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -3290.574% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 64.41% |
| ScandiDos AB (publ) | 60.42 Million SEK | 86.31% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.721% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 94.623% |
| Senzime AB (publ) | 35.75 Million SEK | 76.861% |
| SpectraCure AB (publ) | 318 Thousand SEK | -2501.572% |
| Stille AB | 294.89 Million SEK | 97.195% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.764% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 98.615% |